Sernova Corp
Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Bio… Read more
Sernova Corp (SEOVF) - Net Assets
Latest net assets as of October 2025: $-25.08 Million USD
Based on the latest financial reports, Sernova Corp (SEOVF) has net assets worth $-25.08 Million USD as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($764.23K) and total liabilities ($25.84 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-25.08 Million |
| % of Total Assets | -3281.3% |
| Annual Growth Rate | N/A |
| 5-Year Change | -189.34% |
| 10-Year Change | -566.2% |
| Growth Volatility | 179.12 |
Sernova Corp - Net Assets Trend (2012–2025)
This chart illustrates how Sernova Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sernova Corp (2012–2025)
The table below shows the annual net assets of Sernova Corp from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-10-31 | $-25.08 Million | -93.54% |
| 2024-10-31 | $-12.96 Million | -203.53% |
| 2023-10-31 | $12.51 Million | -73.71% |
| 2022-10-31 | $47.61 Million | +69.62% |
| 2021-10-31 | $28.07 Million | +577.19% |
| 2020-10-31 | $4.14 Million | -15.09% |
| 2019-10-31 | $4.88 Million | +49.56% |
| 2018-10-31 | $3.26 Million | -10.59% |
| 2017-10-31 | $3.65 Million | -32.13% |
| 2016-10-31 | $5.38 Million | +82.13% |
| 2015-10-31 | $2.95 Million | -11.99% |
| 2014-10-31 | $3.36 Million | -41.84% |
| 2013-10-31 | $5.77 Million | -4.98% |
| 2012-10-31 | $6.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sernova Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16610260800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $141.03 Million | % |
| Total Equity | $-25.08 Million | 100.00% |
Sernova Corp Competitors by Market Cap
The table below lists competitors of Sernova Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rottneros AB
ST:RROS
|
$34.31 Million |
|
National Energy Services Reunited Corp Warrants
NASDAQ:NESRW
|
$34.33 Million |
|
Summit Bancshares Inc
PINK:SMAL
|
$34.34 Million |
|
LUMENT FINANCE TR. DL-01
F:70X
|
$34.35 Million |
|
Sotherly Hotels Inc
NASDAQ:SOHO
|
$34.31 Million |
|
Silver One Resources Inc
OTCQX:SLVRF
|
$34.30 Million |
|
Electrocore LLC
NASDAQ:ECOR
|
$34.30 Million |
|
Gemina Laboratories Ltd
OTCQB:GLABF
|
$34.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sernova Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -12,956,608 to -25,076,830, a change of -12,120,222.
- Net loss of 15,743,466 reduced equity.
- New share issuances of 248,639 increased equity.
- Other factors increased equity by 3,374,605.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-15.74 Million | -62.78% |
| Share Issuances | $248.64K | +0.99% |
| Other Changes | $3.37 Million | +13.46% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Sernova Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-10-31 | $0.00 | $0.13 | x |
| 2016-10-31 | $0.00 | $0.13 | x |
| 2017-10-31 | $0.02 | $0.13 | x |
| 2018-10-31 | $0.02 | $0.13 | x |
| 2019-10-31 | $0.02 | $0.13 | x |
| 2020-10-31 | $0.02 | $0.13 | x |
| 2021-10-31 | $0.11 | $0.13 | x |
| 2022-10-31 | $0.16 | $0.13 | x |
| 2023-10-31 | $0.04 | $0.13 | x |
| 2024-10-31 | $-0.04 | $0.13 | x |
| 2025-10-31 | $-0.08 | $0.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sernova Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-71.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 1.02x | $-607.26K |
| 2013 | 0.00% | 0.00% | 0.00x | 1.04x | $-577.03K |
| 2014 | -72.63% | 0.00% | 0.00x | 1.06x | $-2.77 Million |
| 2015 | -96.82% | 0.00% | 0.00x | 1.07x | $-3.15 Million |
| 2016 | -46.47% | 0.00% | 0.00x | 1.16x | $-3.04 Million |
| 2017 | -72.31% | 0.00% | 0.00x | 1.25x | $-3.00 Million |
| 2018 | -113.32% | 0.00% | 0.00x | 1.10x | $-4.03 Million |
| 2019 | -81.35% | 0.00% | 0.00x | 1.14x | $-4.46 Million |
| 2020 | -128.38% | 0.00% | 0.00x | 1.38x | $-5.74 Million |
| 2021 | -24.82% | 0.00% | 0.00x | 1.06x | $-9.77 Million |
| 2022 | -51.29% | 0.00% | 0.00x | 1.10x | $-29.18 Million |
| 2023 | -311.62% | 0.00% | 0.00x | 1.77x | $-40.25 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-30.90 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.24 Million |
Industry Comparison
This section compares Sernova Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sernova Corp (SEOVF) | $-25.08 Million | 0.00% | N/A | $34.31 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |